2001
DOI: 10.1016/s0006-8993(01)02328-9
|View full text |Cite
|
Sign up to set email alerts
|

Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

4
131
0

Year Published

2002
2002
2013
2013

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 189 publications
(135 citation statements)
references
References 33 publications
4
131
0
Order By: Relevance
“…Endangered neurons can release proinflammatory chemokines such as monocyte chemoattractant protein-1 (MCP-1/CCL2) and secondary lymphoid-tissue chemokine (SLC/CCL21). Expression of MCP-1 and SLC is increased in neurons after ischemia [29,30]. Subsequently, recruited and activated microglial cells produce inflammatory mediators, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and nitric oxide (NO), which contribute to delayed neuronal death [31].…”
Section: Discussionmentioning
confidence: 99%
“…Endangered neurons can release proinflammatory chemokines such as monocyte chemoattractant protein-1 (MCP-1/CCL2) and secondary lymphoid-tissue chemokine (SLC/CCL21). Expression of MCP-1 and SLC is increased in neurons after ischemia [29,30]. Subsequently, recruited and activated microglial cells produce inflammatory mediators, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and nitric oxide (NO), which contribute to delayed neuronal death [31].…”
Section: Discussionmentioning
confidence: 99%
“…However, a significant upregulation or dysregulation of CNS expression of CCL2 occurs in a variety of acute and chronic neuroinflammatory and neurodegenerative CNS disorders, implicating a role for CCL2 in pathological conditions. For example, CCL2 levels in the CNS are elevated in brain injury (Little et al, 2006), cerebral ischemia (Che et al, 2001;Minami et al, 2006), multiple sclerosis (Mahad and Ransohoff, 2003;McManus et al, 1998), human immunodeficiency virus (HIV)-associated dementia (Cinque et al, 1998) and Alzheimer's disease (Galimberti et al, 2006). Both neurotoxic and neuroprotective roles for CCL2 have been proposed in these conditions.…”
Section: Introductionmentioning
confidence: 99%
“…In experimental brain ischemia model, MCP-1 messenger RNA and MCP-1 protein in the ischemic cortex are expressed after focal brain ischemia (Che et al, 2001;Kim et al, 1995;Wang et al, 1995). Recent studies using genetic models have reported that MCP-1 deficiency attenuates infarct volume in the murine stroke model (Hughes et al, 2001), and overexpression of MCP-1 causes larger infarct volume and more chemoattraction of monocytes and macrophages into ischemic region than wild-type control (Chen et al, 2003), suggesting that elevated MCP-1 levels might lead to an increased influx of monocytes and evolution of size in brain infarction.…”
mentioning
confidence: 99%